Gemcitabine is indicated in combination with cisplatin as first-line therapy for solid tumours
including non-small cell lung cancer (NSCLC), bladder cancer and mesothelioma …

Genes involved in all aspects of tumor development and growth can become aberrantly
methylated in tumor cells, including genes involved in apoptosis and cell cycle regulation …

Gemcitabine is a cytotoxic cytidine analog, which is widely used in anti-cancer therapy. One
mechanism by which gemcitabine acts is by inhibiting nucleotide excision repair (NER) …

Purpose The nucleoside analog 5-aza-2′-deoxycytidine (5-aza-CdR, decitabine) is a
potent inhibitor of DNA methylation in vitro. Cellular treatment with this agent induces the re …

The DNA methyltransferase inhibitors azacytidine and decitabine represent archetypal
drugs for epigenetic cancer therapy. To characterize the demethylating activity of azacytidine …

Purpose The DNA methyltransferase inhibitor 5-aza-2′-deoxycytidine (decitabine) induces
DNA demethylation and re-expression of epigenetically silenced genes, and increases …

Although new agents and drug combinations have increased the response rate in advanced
non-small cell lung cancer (NSCLC), long-term survivors are rare. There is an urgent need …

The cytosine analogues 5‐azacytosine (azacytidine) and 2′‐deoxy‐5‐azacytidine
(decitabine) are the currently most advanced drugs for epigenetic cancer therapies. These …

Background Targeting abnormal DNA methylation represents a therapeutically relevant
strategy for cancer treatment as demonstrated by the US Food and Drug Administration …

Purpose: By hypomethylating genes, decitabine may up-regulate factors required for
chemotherapeutic cytotoxicity. Platinum-resistant cells may have reduced expression of the …